Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Butyrophilin subfamily 3 member A2 (BTN3A2 (also known as CD277 isoform A2 in the BTN3 family context))
- Target
- BTN3A2 (also known as CD277 isoform A2 in the BTN3 family context)
- Molecular classification
- Receptor-like immunoglobulin superfamily protein, Immune checkpoint/immune modulatory molecule (B7-like family), Other (cell-surface glycoprotein)
01
Overview
Butyrophilin subfamily 3 member A2 (BTN3A2) is a cell-surface glycoprotein of the immunoglobulin superfamily located at the plasma membrane, with two extracellular Ig domains and lacking the intracellular B30.2 domain that is present in BTN3A1; it modulates T-cell responses in adaptive immunity and can inhibit IFN-γ release from activated T cells. BTN3A family members share high structural homology with the B7 superfamily and form V-shaped ectodomain homodimers; antibodies binding the BTN3 ectodomain can modulate Vγ9Vδ2 T-cell activation, highlighting the family’s role in immune regulation relevant to infection and tumor immunity.
- Other names
- BTN3A2Butyrophilin-like protein 2BT3.2CD277 (BTN3 family designation)Butyrophilin, subfamily 3, member A2
02
Mechanism of action
Antibody binding to BTN3A ectodomain modulates γδ T-cell activation (agonist 20.1 mimics phosphoantigen-mediated activation; antagonist 103.2 inhibits), demonstrating immune-modulatory mechanism via BTN3 family surfaces
03
Biological functions
Immune response modulationRegulation of T-cell responses in adaptive immunityInhibition of interferon-gamma (IFN-γ) release from activated T cellsForms extracellular V-shaped homodimers via C-type Ig domain
04
Disease associations
Cancer (modulates intratumoral immune cell infiltration; BTN3 family studied in tumor immunity)Infection (BTN3 family involved in γδ T-cell responses to infection; BTN3A1 is necessary, BTN3A2 structurally related and part of the complex)
05
Safety considerations
Class-related concern: immune modulation may risk immune-related adverse effects (e.g., off-tumor T-cell activation or suppression) inferred from immune checkpoint targeting generally; direct BTN3A2-specific clinical safety data are limited in cited sources
06
Interacting drugs
No approved small-molecule drugs specifically targeting BTN3A2 identified in public references; BTN3 family-targeting antibodies (e.g., experimental agonist 20.1 and antagonist 103.2) bind BTN3 ectodomains in structural/functional studies
07
Biomarkers
BTN3A2 expression as a potential biomarker of immune modulation in tumors (epithelial expression associated with intratumoral immune infiltration in BTN3/BT3.2 studies)
Beyond the preview
Go deeper on Butyrophilin subfamily 3 member A2 (BTN3A2 (also known as CD277 isoform A2 in the BTN3 family context)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Butyrophilin subfamily 3 member A2 (BTN3A2 (also known as CD277 isoform A2 in the BTN3 family context)).